Research programme: glucose metabolism disorder therapeutics - Adocia
Alternative Names: BC GlaD; BC GlaLira; BioChaperone glargine dulaglutide; BioChaperone Glargine GLP-1; BioChaperone glargine liraglutide; BioChaperone® GlaLira; BioChaperone® Glucagon GLP1Latest Information Update: 28 Feb 2023
At a glance
- Originator Adocia
- Class Antihyperglycaemics; Glucagon-like peptides; Insulins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists; Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Diabetes-mellitus in France (SC)
- 11 Feb 2021 Preclinical development of glucose metabolism disorder therapeutics is ongoing in France (Adocia pipeline, February 2021)
- 11 Feb 2021 Research programme: glucose metabolism disorder therapeutics - Adocia is available for licensing as of 11 Feb 2021. https://www.adocia.com/products-pipeline/